1.33
-0.10 (-6.96%)
| Previous Close | 1.43 |
| Open | 1.40 |
| Volume | 7,665 |
| Avg. Volume (3M) | 110,303 |
| Market Cap | 20,613,170 |
| Price / Sales | 0.710 |
| Price / Book | 11.21 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 - 18 Aug 2025 |
| Profit Margin | -129.05% |
| Operating Margin (TTM) | -163.99% |
| Diluted EPS (TTM) | -2.54 |
| Quarterly Revenue Growth (YOY) | 83.00% |
| Total Debt/Equity (MRQ) | 1,196.16% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | -29.22 M |
| Levered Free Cash Flow (TTM) | -15.22 M |
| Return on Assets (TTM) | -50.88% |
| Return on Equity (TTM) | -1,094.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | CASI Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 43.76% |
| % Held by Institutions | 23.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Mar 2025 | 1,329,383 |
| Wellington Shields Capital Management, Llc | 31 Mar 2025 | 90,894 |
| Adar1 Capital Management, Llc | 31 Mar 2025 | 47,420 |
| Wellington Shields & Co., Llc | 31 Mar 2025 | 30,091 |
| 52 Weeks Range | ||
| Median | 4.00 (200.64%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 May 2025 | 4.00 (200.64%) | Buy | 1.91 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 May 2025 | Announcement | CASI Pharmaceuticals Provides Business and Clinical Update |
| 16 May 2025 | Announcement | CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results |
| 12 May 2025 | Announcement | CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China |
| 07 May 2025 | Announcement | CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |